TissueTech welcomes Ted Davis as CEO

– USA, FL –  TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products today announced the appointment of Ted Davis as the new president and CEO, succeeding founder and former CEO Amy Tseng who remains a member of the board of directors.

“On behalf of the board, I welcome Ted to TissueTech. His experience in strategic business development across the biologics, orthopedics, and life sciences sectors will be instrumental as we transform from a tissue-based manufacturer to a biologics therapy provider. We’re excited about what’s ahead,” said Board Chairman, Robert White.

About Ted Davis

Davis most recently served for five years as president and CEO of Active Implants, LLC, a medical device company focused on the knee preservation segment of sports medicine. He began his career with a decade in the life sciences venture capital field, then transitioned into operating leadership roles at Wright Medical Technology and MicroPort Orthopedics before joining Active Implants, where he is still on the board of directors. Davis also currently serves on the boards of Axis Spine Technologies, Ltd. and SIbone, Inc.

“It is an honor to be only the second CEO in TissueTech’s 25-year history. I have watched the company for more than a decade and have been impressed with its platform technology, clinical outcomes, and surgeon support,” said Ted Davis. “With the addition of ongoing clinical programs to secure biologics license applications for indications to address significant unmet clinical needs in the ophthalmology, orthopedics, and wound management segments, TissueTech is poised to secure its position as a leader in regenerative medicine—now and into the future.”

About TissueTech, Inc.

TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane products are processed using its proprietary CRYOTEK cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with its products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology.

For more information: https://tissuetech.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.